TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.

Breast cancer frequently metastasizes to the skeleton, and the associated bone destruction is mediated by the osteoclast. Growth factors, including transforming growth factor-beta (TGF-beta), released from bone matrix by the action of osteoclasts, may foster metastatic growth. Because TGF-beta inhibits growth of epithelial cells, and carcinoma cells are often defective in TGF-beta responses, any role of TGF-beta in metastasis is likely to be mediated by effects on the surrounding normal tissue. However, we present evidence that TGF-beta promotes breast cancer metastasis by acting directly on the tumor cells. Expression of a dominant-negative mutant (TbetaRIIDeltacyt) of the TGF-beta type II receptor rendered the human breast cancer cell line MDA-MB-231 unresponsive to TGF-beta. In a murine model of bone metastases, expression of TbetaRIIDeltacyt by MDA-MB-231 resulted in less bone destruction, less tumor with fewer associated osteoclasts, and prolonged survival compared with controls. Reversal of the dominant-negative signaling blockade by expression of a constitutively active TGF-beta type I receptor in the breast cancer cells increased tumor production of parathyroid hormone-related protein (PTHrP), enhanced osteolytic bone metastasis, and decreased survival. Transfection of MDA-MB-231 cells that expressed the dominant-negative TbetaRIIDeltacyt with the cDNA for PTHrP resulted in constitutive tumor PTHrP production and accelerated bone metastases. These data demonstrate an important role for TGF-beta in the development of breast cancer metastasis to bone, via the TGF-beta receptor-mediated signaling pathway in tumor cells, and suggest that the bone destruction is mediated by PTHrP.

[1]  R. Coffey,et al.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Klagsbrun,et al.  Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. , 1986, The Journal of biological chemistry.

[3]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.

[4]  G. Strewler,et al.  Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. , 1987, The Journal of clinical investigation.

[5]  A. F. Stewart,et al.  Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. , 1987, The Journal of biological chemistry.

[6]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[7]  M. Pandian,et al.  Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. , 1992, Clinical chemistry.

[8]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[9]  Irene L Andrulis,et al.  MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.

[10]  B F Boyce,et al.  Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. , 1995, Cancer research.

[11]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[12]  M. Freeman,et al.  A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. , 1991, Science.

[13]  Jane M. Moseley,et al.  Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? , 1993, Molecular and Cellular Endocrinology.

[14]  G. Mundy,et al.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Chirgwin,et al.  Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[16]  J. Willson,et al.  Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells , 1994 .

[17]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[18]  M. Freeman,et al.  Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R Wieser,et al.  Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region , 1993, Molecular and cellular biology.

[20]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[21]  J. Graff,et al.  Smad3 Mutant Mice Develop Metastatic Colorectal Cancer , 1998, Cell.

[22]  J. Massagué,et al.  Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin , 1994, Molecular and cellular biology.

[23]  C. Caulin,et al.  Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[24]  L. Wakefield,et al.  Expression of a dominant‐negative mutant TGF‐β type II receptor in transgenic mice reveals essential roles for TGF‐β in regulation of growth and differentiation in the exocrine pancreas , 1997 .

[25]  J. Massagué,et al.  TGF- SIGNAL TRANSDUCTION , 1998 .

[26]  J. Hayman,et al.  Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. , 1991, Cancer research.

[27]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[28]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[29]  A. Boyde,et al.  Scanning electron microscopy in bone pathology: review of methods, potential and applications. , 1986, Scanning electron microscopy.

[30]  R. Warrell,et al.  Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. , 1990, The New England journal of medicine.

[31]  L. Suva,et al.  Parathyroid hormone-related protein purified from a human lung cancer cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Uitto,et al.  Revertant Mosaicism in Epidermolysis Bullosa Caused by Mitotic Gene Conversion , 1997, Cell.

[33]  T. Rosol,et al.  Effects of transforming growth factor-beta on parathyroid hormone-related protein production and ribonucleic acid expression by a squamous carcinoma cell line in vitro. , 1994, Endocrinology.

[34]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[35]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[36]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[37]  L. Reimer,et al.  Scanning Electron Microscopy , 1984 .

[38]  T. Martin,et al.  Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein. , 1996, Endocrinology.

[39]  N. Rosen,et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.

[40]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[41]  Hiroyuki Miyoshi,et al.  Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes , 1998, Cell.

[42]  M. Kretzschmar,et al.  Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1 , 1997, Nature.

[43]  J. Hayman,et al.  Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. , 1990, Cancer research.

[44]  L. Wakefield,et al.  Transgenic Mice Overexpressing a Dominant-negative Mutant Type II Transforming Growth Factor β Receptor Show Enhanced Tumorigenesis in the Mammary Gland and Lung in Response to the Carcinogen 7,12-Dimethylbenz-[a]-anthracene , 1997 .

[45]  J. Ratcliffe,et al.  Parathyroid hormone related protein and hypercalcaemia in breast cancer. , 1991, BMJ.

[46]  J. Massagué,et al.  GS domain mutations that constitutively activate T beta R‐I, the downstream signaling component in the TGF‐beta receptor complex. , 1995, The EMBO journal.

[47]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.